AgomAb Therapeutics (NASDAQ:AGMB) Raised to Hold at Zacks Research

AgomAb Therapeutics (NASDAQ:AGMB) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

AGMB has been the subject of a number of other reports. JPMorgan Chase & Co. initiated coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “overweight” rating and a $32.00 price objective for the company. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a research note on Tuesday, February 17th. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $28.00 price target on the stock. Finally, Leerink Partners initiated coverage on AgomAb Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

AgomAb Therapeutics Stock Performance

NASDAQ:AGMB opened at $14.21 on Wednesday. AgomAb Therapeutics has a 12-month low of $12.66 and a 12-month high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.